These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1035 related items for PubMed ID: 26354527

  • 1. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
    Heigener DF, Schumann C, Sebastian M, Sadjadian P, Stehle I, Märten A, Lüers A, Griesinger F, Scheffler M, Afatinib Compassionate Use Consortium (ACUC).
    Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
    [Abstract] [Full Text] [Related]

  • 2. [A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].
    Wislez M, Malka D, Bennouna J, Mortier L, Bensadoun RJ, Sicard J, Dielenseger P, Rey JB, Moro-Sibilot D, Scotté F.
    Bull Cancer; 2014 Jun; 101(6):647-52. PubMed ID: 24977454
    [Abstract] [Full Text] [Related]

  • 3. Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
    Schuler M, Fischer JR, Grohé C, Gütz S, Thomas M, Kimmich M, Schneider CP, Laack E, Märten A, Afatinib Compassionate Use Consortium.
    Oncologist; 2014 Oct; 19(10):1100-9. PubMed ID: 25232040
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
    Lee VH, Leung DK, Choy TS, Lam KO, Lam PM, Leung TW, Kwong DL.
    BMC Cancer; 2016 Feb 24; 16():147. PubMed ID: 26911310
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
    Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC.
    Clin Cancer Res; 2011 Jun 01; 17(11):3812-21. PubMed ID: 21531810
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K, Hata A, Takeshita J, Okuda C, Kaji R, Masago K, Fujita S, Katakami N.
    Cancer Chemother Pharmacol; 2015 Oct 01; 76(4):835-41. PubMed ID: 26349474
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH, Soo RA.
    Drug Des Devel Ther; 2015 Oct 01; 9():5641-53. PubMed ID: 26508839
    [Abstract] [Full Text] [Related]

  • 10. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.
    J Clin Oncol; 2008 May 20; 26(15):2442-9. PubMed ID: 18458038
    [Abstract] [Full Text] [Related]

  • 11. Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence.
    Ke EE, Wu YL.
    Ther Adv Respir Dis; 2016 Jun 20; 10(3):256-64. PubMed ID: 26929305
    [Abstract] [Full Text] [Related]

  • 12. Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
    van der Wekken AJ, Kuiper JL, Saber A, Terpstra MM, Wei J, Hiltermann TJN, Thunnissen E, Heideman DAM, Timens W, Schuuring E, Kok K, Smit EF, van den Berg A, Groen HJM.
    PLoS One; 2017 Jun 20; 12(8):e0182885. PubMed ID: 28854272
    [Abstract] [Full Text] [Related]

  • 13. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
    Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL.
    Lancet Oncol; 2015 Jul 20; 16(7):830-8. PubMed ID: 26051236
    [Abstract] [Full Text] [Related]

  • 14. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.
    Brückl W, Tufman A, Huber RM.
    Expert Rev Anticancer Ther; 2017 Feb 20; 17(2):143-155. PubMed ID: 27898252
    [Abstract] [Full Text] [Related]

  • 15. Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience.
    Ezeife DA, Melosky B, Tudor R, Lin S, Lau A, Panzarella T, Leighl NB.
    Curr Oncol; 2018 Oct 20; 25(5):e385-e390. PubMed ID: 30464688
    [Abstract] [Full Text] [Related]

  • 16. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
    Sasaki S, Yoshioka Y, Ko R, Katsura Y, Namba Y, Shukuya T, Kido K, Iwakami S, Tominaga S, Takahashi K.
    Respir Investig; 2016 Jan 20; 54(1):14-9. PubMed ID: 26718140
    [Abstract] [Full Text] [Related]

  • 17. [Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation].
    Vidal ÓJ.
    Med Clin (Barc); 2016 Apr 20; 146 Suppl 1():12-8. PubMed ID: 27426243
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.
    Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schütz M, Serke M, Stöhlmacher-Williams J, Märten A, Maria Huber R, Dickgreber NJ, Afatinib Compassionate Use Consortium (ACUC).
    J Thorac Oncol; 2015 Jan 20; 10(1):156-63. PubMed ID: 25247337
    [Abstract] [Full Text] [Related]

  • 19. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.
    Jpn J Clin Oncol; 2012 Jun 20; 42(6):528-33. PubMed ID: 22457323
    [Abstract] [Full Text] [Related]

  • 20. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
    Kim MH, Choi CM, Lee SY, Park CK, Chang YS, Lee KY, Kim SJ, Yang SH, Ryu JS, Lee JE, Lee SY, Park CK, Lee SH, Jang SH, Yoon SH, Jang TW.
    Anticancer Res; 2022 Mar 20; 42(3):1615-1622. PubMed ID: 35220259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.